What is the recommended cyproheptadine syrup dose for appetite stimulation?

Cyproheptadine Syrup Dosing for Low Appetite

For appetite stimulation in children, start with 2 mg (0.5 mL of syrup) two to three times daily for ages 2-6 years, or 4 mg two to three times daily for ages 7-14 years, with doses timed before meals to optimize appetite during eating. 1

FDA-Approved Dosing by Age

Children Ages 2-6 Years

• Standard dose: 2 mg (0.5 tablet or equivalent syrup volume) two to three times daily 1
• Weight-based calculation: Approximately 0.25 mg/kg/day or 8 mg/m² body surface area 1
• Maximum daily dose: 12 mg/day 1

Children Ages 7-14 Years

• Standard dose: 4 mg (1 tablet or equivalent syrup volume) two to three times daily 1
• Maximum daily dose: 16 mg/day 1

Adults

• Starting dose: 4 mg three times daily 1
• Therapeutic range: 4-20 mg/day, with most patients requiring 12-16 mg/day 1
• Maximum: 0.5 mg/kg/day, not to exceed 32 mg/day 1

Optimal Timing Strategy

Administer doses strategically before lunch and dinner when stimulant effects peak (if used for stimulant-induced appetite suppression) to maximize meal intake. 2

• Time doses 30-60 minutes before main meals to optimize gastric accommodation and appetite during eating 2
• For stimulant-related appetite loss, ensure the child is on the minimum effective stimulant dose before adding cyproheptadine 2

Response Assessment and Titration

Evaluate clinical response after 1-2 weeks of therapy and adjust dosing based on weight gain and tolerability. 2

• Weight monitoring: Obtain objective weight measurements at baseline and every 2-4 weeks during titration 2
• Expected outcomes: Studies show mean weight gain of 1.61 kg over 12 weeks in controlled trials 3
• Efficacy timeline: Most patients show improvement within 14 days, with continued benefit over 3-4 months 4

Evidence-Based Efficacy

The medication demonstrates robust effectiveness across multiple populations:

• Functional GI disorders: 72.8% of children achieved complete symptom improvement at mean dose of 0.14 mg/kg/day 5
• Stimulant-induced weight loss: All 21 patients in one study gained weight (mean 2.2 kg) with mean dose of 4.9 mg/day 4
• Cystic fibrosis: Significant weight gain (1.61 kg vs 0.67 kg placebo) with 4 mg three times daily for 12 weeks 3
• General poor appetite: 67% showed significant positive effect in children under 3 years, with starting doses ranging 0.069-0.825 mg/kg/day 6

Safety Profile and Side Effects

Cyproheptadine is generally well-tolerated, with drowsiness (13%) and weight gain (10%) being the most common side effects. 5

• Most frequent: Transient mild to moderate sedation, which typically resolves with continued use 7, 8
• Less common: Constipation (rare in pediatric studies) 6
• Rare but serious: Hepatotoxicity occurs at an estimated frequency of 0.27-1.4 per 1000 patients, regardless of age 7
• Special caution: Use carefully in children with epilepsy, as convulsions have been reported 9

Clinical Pitfalls to Avoid

Do not confuse the chronic low-dose appetite stimulation regimen (0.14-0.25 mg/kg/day) with the acute high-dose serotonin syndrome treatment (0.25 mg/kg per dose, repeated). 10, 9

• The serotonin syndrome indication uses much higher total daily doses and is a completely different clinical scenario 11
• Starting doses that are too high increase sedation without improving efficacy 6
• Failure to time doses appropriately before meals reduces effectiveness 2

Alternative Considerations

Before initiating cyproheptadine, optimize meal caloric density, adjust stimulant timing if applicable, and verify the child is on the minimum effective dose of any appetite-suppressing medications. 2

• Consider megestrol acetate as second-line therapy only after 4 weeks of failed cyproheptadine trial, particularly in oncology patients, though it carries higher risks including cortisol suppression 10
• Studies in malignant/progressive disease states (HIV, cancer) show minimal benefit compared to other populations 8

Monitoring Requirements

• Baseline: Weight, BMI, liver function tests (given rare hepatotoxicity risk) 7
• Follow-up: Weight every 2-4 weeks during titration, then monthly 2
• Duration: Most studies demonstrate sustained benefit over 12-16 weeks 5, 4, 3
• Discontinuation criteria: If no weight gain or appetite improvement after 4 weeks at therapeutic doses, consider alternative approaches 10